Cancer in pregnancy: a dedicated database was set up in order to keep a track of patients with cancer during pregnancy. Whenever possible, blood and tissue samples are collected and conserved in the biobank if the patient has either chemotherapy or surgery during pregnancy. Data are sent anonymously to a European database in order to increase numbers and draw conclusions about short and long term safety of these treatments during pregnancy and long term outcome of offsprings.
Robotic assisted surgery: robotic assisted surgery is an emerging surgical technique. Preliminary studies show a potential benefit for gynecologic oncology patients. These supposed benefits still need confirmation and will be evaluated through prospective studies.
The Altug group develops cutting edge on-chip optical bio-detection and spectroscopy technologies for biomedical research in cancer and neurodegenerative diseases, early disease detection, and point-of-care applications. In particular, the group introduces new label-free, quantitative, real-time and high-throughput screening technologies, low-cost and portable biosensors.
The Radiation Oncology group is interested in head and neck carcinoma clinical research from early phase I to large phase III clinical trials. Furthermore, a second key point of interest is translational research in radiotherapy embracing several aspects such as innovation in radiotherapy delivery and imaging, predictive markers for tumor response, and combining new molecular targeted drugs with radiotherapy. In addition, the group is dedicated to evaluating the differential effect associated with new types of ultra-high dose rate radiotherapy.
The Bucher group is interested in gene regulation in higher organism. The general objective is to reverse-engineer gene regulatory networks from genomics data, in particular networks relevant to human health. To this end, the group develops novel bioinformatics algorithms to extract knowledge from new data types. In addition they develop and maintain public bioinformatics web servers.
Prof. Buclin’s research focuses specifically on the following studies: population pharmacokinetics of targeted anticancer agents, pharmacokinetic-pharmacodynamic relationships relevant to optimize therapeutic efficacy and tolerability, quantification and identification of sources of variability in drug response, development of therapeutic concentration monitoring approaches to individualize the administration of critical treatments.
Dr. Stéphane Cherix is mainly active in clinical research, mostly in oncologic fields, but also in general orthopaedic surgery and traumatology.
Efficiency of new treatment modalities, like percutaneous cryoablation therapy, that can be associated to surgery, on musculoskeletal tumours metastases, has been one of his major domains of interest in the last years.
The Constam group uses biochemical and genetic approaches to study the regulation and function of TGFβ signals during embryogenesis and at the interface of cancer cells and their microenvironment. The goal is to harness such activities for stem cell therapies and to block oncogenic functions.
We investigate fundamental mechanisms in the tumor microenvironment (TEM) that determine the fate of antitumor immunity, focusing on two important aspects: First, we investigate the deregulation of tumor-infiltrating lymphocytes (TILs) to understand their functional specificity and avidity, and the external influences and signaling reprogramming underlying their dysfunction in tumors. This line of investigation is expected to yield novel pharmacologic approaches to restore antitumor immunity as well as novel methodologies to select and expand TILs for adoptive therapy. Second, we investigate the tumor vasculature as a barrier to effective T cell infiltration in many tumors, but also as a potential target for therapy. The lab is pursuing T cell engineering approaches as a means to address the deregulation of T cells in the TME, and for redirecting them against relevant tumor targets, including the vasculature. Mouse models with human bone marrow are used to test these therapeutics. Clinical translation is a high priority. A GMP facility will support the development of clinical trials using adoptive T cell therapy approaches.
Prof. Csajka’s research focuses on population pharmacokinetic, pharmacodynamic and pharmacogenetic modeling of pharmaceutical agents. The objectives are to better characterize the dose-concentration-response and toxicity relationships, either for marketed drugs or during their clinical development. This approach allows the development of Bayesian feedback strategies for dosage regimen individualization.
Prof. de Leval’s team is committed to implementing and optimizing tools for the molecular diagnosis of hematological malignancies and other cancers, to characherizing lymphomas and other hematopoietic neoplasms clinically, to understanding the molecular mechanisms underlying NK/T-cell malignancies, and to studying thymic malignancies.
We investigate the mechanisms whereby macrophages promote tumor angiogenesis, immunosuppression and progression, thus limiting the efficacy of antiangiogenic, chemo- and immuno-therapies. This is being studied in genetically engineered mouse models (GEMM) of cancer, in which macrophages are pharmacologically targeted or genetically modified to be visualized, depleted, or to modulate their gene expression in the context of anticancer treatments.
Prof. Decosterd’s core research interests embrace the four following activities: analytical development and validation; instrumental analysis; ultra and high performance liquid chromatography coupled to triple quadripole tandem mass spectrometry (HPLC-MS/MS; UPLC-MS/MS) to respond efficiently to analytical demands from large-scale clinical research programs in the field of pharmacogenetics and pharmacokinetics of current and new targeted anticancer therapy; high-throughput multiplex assays for the Therapeutic Drug Monitoring (TDM) of current and new classes of targeted anticancer agents, antiretrovirals, antifungals, antibiotics and new antimalarial combinations regimens.
Prof. Delaloye’s clinical interests are focused on breast and uterine cancers. First he explored the mechanisms and pathways of lymphatic dissemination in endometrial cancer. He now collaborates with researchers trying to elucidate 1) the pathways and the microenvironmental signals governing the pro-angiogenic activities of monocytes expressing the Tie-2/Tek receptor tyrosine kinase in early breast cancer, 2) interactions between cancer stem cells and metastases, 3) hormonal control on breast carcinogenesis. He is concerned by supportive care in breast cancer.
The team contributes as bioinformatics experts to biomedical projects, analyzing last generation data for discovery in the fields of gene expression profiling and regulation, cancer subtypes, as well as developing mathematical models of prognosis and studying biomarker discovery and validation methodology.
Prof. Demartines’s research interests include the entire perioperative management and minimal invasive approaches especially in oncologic patients. In this field, nutrition and Enhanced Recovery After Surgery programs (ERAS) are very important. Furthermore, the influence of postoperative complications on oncological outcome, multimodal treatment of non-operable liver metastasis, HIPEC and PIPAC are in the research field of his Department.
The LSBG is developing and using high-throughput sequencing, microfluidics, large-scale yeast screening, and computational approaches to characterize the regulatory code in Drosophila and mammals and to examine how variations in this code affect molecular and organismal diversity.